Chaplin Andrei V, Sykilinda Nina N, Skvortsov George A, Troshin Konstantin S, Vasilyeva Anna A, Shuraleva Sofia A, Malkov Artem A, Simonov Vladislav S, Efimov Boris A, Kafarskaia Lyudmila I, Miroshnikov Konstantin A, Kuznetsova Anna A, Evseev Peter V
Pirogov Russian National Research Medical University, Ostrovityanova 1, 117997 Moscow, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str. 16/10, 117997 Moscow, Russia.
Viruses. 2025 Aug 6;17(8):1088. doi: 10.3390/v17081088.
Antibiotic-resistant presents a critical global health challenge, particularly in hospital-acquired infections. Bacteriophages offer a promising therapeutic avenue due to their ability to target and lyse resistant strains. This study characterizes phage Banzai, a newly isolated (family ) with lytic activity against multiple isolates, including multidrug-resistant strains. Genomic analysis revealed a 66,189 bp genome, lacking antibiotic resistance or virulence factors, and suggested a headful packaging mechanism and the presence of a bidirectional component in the replication. In vivo experiments using showed therapeutic potential, significantly improving larval survival (87% at 24 h). Host range analysis revealed activity against 13 of 30 isolates, including members of O1, O3, O5 and O6 in silico predicted serogroups. Phylogenomic analyses place phage Banzai within the genus , sharing 94.8% intergenomic similarity with its closest relatives, supporting its classification as a novel species. These findings highlight phage Banzai as a potential candidate for phage therapy, demonstrating genomic stability, a strictly lytic lifestyle, and in vivo efficacy.
抗生素耐药性是一项严峻的全球健康挑战，在医院获得性感染中尤为突出。噬菌体因其能够靶向并裂解耐药菌株而提供了一条有前景的治疗途径。本研究对噬菌体“万岁”进行了表征，它是一种新分离的（科），对多种分离株具有裂解活性，包括多重耐药菌株。基因组分析揭示了一个66,189 bp的基因组，缺乏抗生素耐药性或毒力因子，并提示了一种满头部包装机制以及复制过程中双向元件的存在。使用进行的体内实验显示出治疗潜力，显著提高了幼虫存活率（24小时时为87%）。宿主范围分析揭示了对30株分离株中的13株具有活性，包括在计算机预测血清群中的O1、O3、O5和O6成员。系统基因组分析将噬菌体“万岁”置于属内，与其最亲近的亲属共享94.8%的基因组间相似性，支持其作为一个新物种的分类。这些发现突出了噬菌体“万岁”作为噬菌体治疗潜在候选者的地位，证明了其基因组稳定性、严格的裂解生活方式和体内疗效。
需注意，原文中部分括号内容缺失具体信息，翻译可能会稍显生硬，但已尽量忠实原文进行翻译。
